Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares ...

Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...

Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...

Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...

Stock analysts at Leerink Partnrs decreased their Q4 2025 earnings per share (EPS) estimates for Illumina in a note issued to ...

Leerink Partnrs analyst M. Cherny now forecasts that the medical research company will post earnings of $14.53 per share for ...

Walgreens Boots Alliance beat analysts' lowered expectations for first-quarter adjusted profit and maintained its annual ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.88% ...

Leerink Partners analyst Faisal Khurshid has maintained their neutral stance on GLPG stock, giving a Hold rating on December 23.Stay Ahead of ...

On Monday, Leerink Partners sustained their Outperform rating and $110.00 price target for Axsome Therapeutics (NASDAQ:AXSM) shares. The firm's stance comes in the wake of recent clinical trial ...

On Monday, Leerink Partners sustained their Outperform rating and $110.00 price target for Axsome Therapeutics (NASDAQ:AXSM) shares. The firm's stance comes in the wake of recent clinical trial ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...